T-Cell Immunotherapy Market (2nd Edition), 2017-2030

T-Cell Immunotherapy Market (2nd Edition), 2017-2030

The concept of immunotherapies dates back to the 18th century; however, since inception, the field has evolved tremendously and is currently cited as one of the most rapidly growing segments of the pharmaceutical industry. Harnessing immune system components for developing therapeutic solutions has demonstrated significant clinical benefit for various diseases areas, specifically against a number of oncological indications. Immunotherapeutics have gradually gained a strong foothold in the pharmaceutical industry. Post the early success of immune checkpoint inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.

Adoptive immunotherapy is an emerging concept that involves the passive transfer of immune cells, which may or may not be modified / genetically altered to express a desired set of traits and / or features. Characterized by key features such as target specificity, adaptability and the capability to retain immunologic memory, T-cells have been effectively used as therapeutic tools to mediate an artificial immune response. More specifically, T-cell immunotherapies are classified into three major segments, namely chimeric antigen receptor (CAR) T-cell, T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) based therapies. Academicians across the globe have significantly contributed to this field by convening the initial research on potential product candidates; this has served as the intellectual framework for establishment of several start-ups and evolution of the product portfolios of established players in the industry.

The overall market is expected to witness a significant growth in opportunities for a variety of stakeholders in the coming decade. It is important to highlight that various technology providers, aiming to develop and / or support the development of T-cell immunotherapy products with improved efficacy and safety, have designed and introduced advanced platforms for engineering of T-cells. Innovation in this domain, backed by lucrative rounds of venture capital (VC) funding, has led to the discovery of several novel molecular targets and strengthened the research pipelines of companies focused in this space. The capability to target diverse therapeutic areas is amongst the most prominent growth drivers of this market.

SCOPE OF THE REPORT
The “T-Cell Immunotherapy Market, 2017-2030 (2nd edition)” report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. Immuno-oncology has been gradually nurtured by researchers over the last several years and is now considered as the fourth major pillar of cancer therapy, after surgery, chemotherapy and radiotherapy. As indicated earlier, the T-cell therapy market has evolved significantly over the last few years, offering promising opportunities for a variety of stakeholders. The domain is characterized by a robust and opportunistic pipeline of product candidates focused on targeting hematological cancers and solid tumors. However, with no marketed products, this emerging field is still in its infancy. The report provides a comprehensive overview of the market, focusing particularly on CAR-T therapies, TCR therapies and TIL therapies.

The role of academic players / research institutes has been critical in this domain. Post the establishment of initial proof-of-concept, several industry players have entered into collaboration with non-industry participants to fund the clinical and commercial development of potential product candidates. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis / University of Pennsylvania), KTE-C19 and HPV-16 E6 TCR (Kite Pharma / National Cancer Institute), and LN-144 (Lion Biotechnologies / National Cancer Institute). As mentioned before, encouraging clinical results have significantly accelerated the progress of these therapies.

Several technology providers, especially those with capabilities in genome editing, and viral and non-viral gene transfer, are also actively involved in this emerging market. Many of these players have entered into partnerships with therapy developers in order to assist in designing novel features to enhance the efficacy and potency of existing T-cell therapies. A prominent example of such a technology is safety switches; these are innovative molecular tools designed to manage known side effects, such as cytokine release syndrome and B-cell aplasia, by allowing control over the expression of certain genes in the engineered cell population.

One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing programs of both small and big pharmaceutical firms in this domain. It is worth mentioning that there is a lot of hope pinned on multiple start-ups, which have received significant backing by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following areas:

The current state of the market with respect to key players, developmental stages of pipeline products (both clinical / preclinical) and target therapeutic indications. In addition, we have also provided an overview of the competitive landscape, key challenges and anticipated future trends within the three major types of T-cell based therapies.
Detailed profiles of candidate therapies that are in the mid to late stages of development (phase I/II or above).

The partnerships that have been established in the recent past, covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product development / commercialization agreements, clinical trial collaborations and joint venture agreements.

Details of innovative technological platforms, such as safety switches, which have contributed significantly in overcoming existing gaps in the therapeutic regimen.

An analysis of the various investments, grants and other types of funding provided to companies focused in this area.

An overview of the various therapeutic areas being addressed by therapy developers, including an assessment of the opportunity offered by both oncological and non-oncological disease indications.

A discussion on the emerging trends on social media and on the popularity of T-cell immunotherapy products on Twitter over the last few years.
Details on novel T-cell immunotherapies that are being investigated, along with their respective mechanisms of action.

A detailed case study on the manufacturing of cell therapy products, highlighting key challenges and a list of contract service providers and in-house manufacturers that are involved in this space.

A discussion on the development and sales potential based on target consumer segments, likely adoption rates and expected pricing based upon different models / approaches.

With most products still in the early stages of clinical development, we have provided informed estimates of the potential future sales of different CAR-T, TCR and TIL therapies. The research, analysis and insights presented in this report are backed by a deep understanding of the key drivers behind the predicted growth. We have provided three market forecast scenarios to add robustness to our model. More specifically, the conservative, base and optimistic forecast scenarios represent three different tracks of the industry’s evolution, taking into account the ambiguities associated with the development and approval of pharmaceutical products. All actual figures have been sourced from publicly available information. All figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. During the course of our research, we identified around 280 T-cell therapies being evaluated across various phases of development. Among these, CAR-T cell products are the most common (67%), followed by TCR (23%) and TIL (10%) based therapies.

2. Overall, 29% of the pipeline therapies are being evaluated in phase II / phase III clinical trials; on the other hand, 38% of the therapies are in the preclinical / discovery stage of development. Examples of promising late-stage therapies include CTL-019 (Novartis), JCAR015 (Juno Therapeutics), KTE-C19 and HPV-16 E6 TCR (Kite Pharma), NY-ESO-1 TCR (Adaptimmune / GSK), LN-144 (Lion Biotechnologies), ALT801 (Altor BioScience) and IMCgp100 (Immunocore).

3. Academic institutions are the leading innovators in this domain. Many universities and research institutes have made significant contributions by investing time and building expertise in the design and development of novel CAR-Ts, TCRs and TILs. We observed that non-industry players are involved in the development of around 50% of all the therapies currently in the pipeline. The most active non-industry players (based upon the number of therapies under development) include the National Cancer Institute, MD Anderson Cancer Center, Baylor College of Medicine, University of Pennsylvania, Chinese PLA General Hospital, Southwest Hospital, Fred Hutchinson Cancer Research Center, Fuda Cancer Hospital, Memorial Sloan Kettering Cancer Center, Uppsala University and City of Hope Medical Center.

4. The market is highly fragmented and characterized by the presence of several start-ups, small pharma and big pharma firms. The key players involved in development of T-cell therapies (based upon the number of candidate therapies in their respective product pipelines) include Juno Therapeutics, Shanghai Genechem, Kite Pharma, Cellular Biomedicine Group, Lion Biotechnologies, Takara Bio, Celgene, Adaptimmune and ZIOPHARM Oncology. AURORA BioPharma, Beijing Doing Biomedical, Bellicum Pharmaceuticals, CARsgen Therapeutics, iCarTAB BioMed, Intrexon, Mustang Bio, Novartis, Sinobioway Cell Therapy, Unum Therapeutics and Shionogi are other players that have more than one clinical stage therapies.

5. In addition to some of the companies outlined above, there are several other start-ups that are focused in this domain; these include (in alphabetical order) Altor BioScience, Autolus, Adicet Bio, Catapult Therapy TCR, Chimeric Therapeutics, Formula Pharmaceuticals, Gadeta, Immatics US, JW Biotechnology, Lion TCR, Leucid Bio, Mustang Therapeutics, Poseida Therapeutics, TILT Biotherapeutics, TNK Therapeutics, Tmunity Therapeutics and Vor Biopharma.

6. Stakeholders have forged synergistic partnerships in order to exploit the commercial potential of their respective assets. Overall, we identified more than 135 partnerships that have been inked in the T-cell immunotherapy field over the period 2005-2016. Most common forms of partnerships were related to research (20%), followed by technology licensing (15%), product discovery, development and commercialization (12%), manufacturing (11%), clinical trials (7%) and acquisitions (7%).

7. Amidst several challenges, including the complexities associated with manufacturing cell-based products, and competition from existing drug / therapy classes (such as monoclonal antibodies, bi-specific antibodies and immune checkpoint inhibitors), therapy developers are engaged in extensive research in order to effectively deal with these issues. Several contract manufacturing organizations with advanced capabilities have emerged to provide manufacturing services for the personalized T-cell based therapies. Examples of the CMOs providing manufacturing services for T-cell therapies include apceth Biopharma, Atlantic Bio GMP, Cell and Gene Therapy Catapult, Cell Therapies, CELLforCURE, Cellular Therapeutics, MolMed and PCT (a Caladrius company).

8. A number of technological advancements have taken place in order to support the development of these therapies; engineered CAR-Ts with switch technologies are amongst the latest additions to next-generation T-cell immunotherapies. Funding from VC firms and strategic investors has been a key enabler to the market’s growth. Notably, close to USD 5 billion has been invested in this domain over the past few years. Several big ticket investments have recently taken place. For instance, Juno Therapeutics raised USD 896.8 million in June 2015, Immunocore raised USD 320 million in July 2015, Kite Pharma raised USD 288 million in December 2015 and Cellectis raised USD 228 million in March 2015.

9. A variety of novel types of immunotherapies, other than CAR-T, TCR and TIL, are expected to emerge in the mid-long term. Companies such as TxCell, Caladrius Biosciences, TRACT Therapeutics, Green Cross Cell and Tmunity Therapeutics, are developing T-regulatory cell based therapies. Other players, namely Opexa Therapeutics, TVAX and Immunovative Therapies, are developing T-cell based vaccines for treating autoimmune disorders and various forms of cancer. Further, Atara Biotherapeutics, Cell Medica and Tessa Therapeutics are working on the development of virus-driven T-cell therapies. A number of companies have developed unique technology platforms based on T-cells. Examples include Targazyme (Fucosylated T-cells), Triumvira (TAC-T cells), Chengdu MedGenCell (PD-1 Knockout Engineered T-cells) and GammaCell Bio-Technologies (γδ T-cells).

10. Overall, we believe the T-cell therapy market is likely to be worth USD 25 billion by 2030, expanding at an annualized growth rate of over 101% during this time period. Specifically, by 2030, the markets for CAR-T and TCR therapies market are likely to be worth over USD 11 billion each. Product candidates, such as KTE-C19, CTL019, NY-ESO-1 TCR, ALT 801 and JCAR017, are expected to emerge as potential blockbusters in the long term.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information. The various secondary sources of information that we use include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 presents an executive summary of the report. It offers a high level view on where the T-cell immunotherapy market is headed in the mid-long term.

Chapter 3 provides a general introduction to T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of oncological indications, the advent of cancer immunotherapy and the factors supporting the growing popularity of T-cell based therapies.

Chapter 4 provides a comprehensive overview of the current landscape of the T-cell immunotherapy market. It features information on various types of therapies that are currently in different stages of development (clinical and preclinical / discovery). It includes a detailed analysis of the T-cell immunotherapy pipeline, specifically, providing information on the most commonly targeted disease indications, current phases of development of individual therapies, specific molecular targets, type of developer(s) and the key companies involved in the development of different types of T-cell therapies, namely CAR-T, TCR and TIL.

Chapter 5 focuses on CAR-T cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It discusses the molecular targets that are currently under investigation, the current challenges in this domain, such as toxicity issues, and other relevant parameters. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

Chapter 6 focuses on TCR cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It discusses the molecular targets that are currently under investigation, the current challenges in this domain, such as toxicity issues, and other relevant parameters. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

Chapter 7 elaborates on the TIL based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. To offer due credit to the work of eminent researchers in this domain, we have mapped the locations of key opinion leaders across the globe. This section also includes detailed profiles of the late stage therapies that are under development. Each profile features a general overview of the therapy and provides information on additional aspects, such as the history of development, clinical trial timeline, clinical trial results, manufacturing information, estimated cost of treatment and details on the treatment regimen itself.

Chapter 8 features an elaborate discussion on the future opportunity presented by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are in the advanced stages of development (phase I/II, phase II and phase II/III), taking into consideration the target patient population, existing competition, likely adoption rates and the likely price of T-cell therapies.

Chapter 9 provides an analysis of the various T-cell therapies that are being developed for the treatment of commonly targeted indications, including hematological cancers and solid tumors. It is worth mentioning that the aforementioned types of oncological indications have been the prime focus of companies developing T-cell immunotherapies. The section also highlights key epidemiological facts and the currently available treatment solutions for each indication.

Chapter 10 focuses on emerging technological platforms that mediate / assist the growth of the T-cell market. It includes detailed discussions on various novel and innovative technologies, along with brief information about key technology providers.
Chapter 11 provides an overview of the emerging trends related to T-cell immunotherapy on social media. It includes data representing the popularity of T-cell products on Twitter over the last five years.

Chapter 12 presents a detailed analysis on the partnerships and agreements established between various players concerning T-cell immunotherapies in the past few years. The section also highlights the financial details of the agreements (wherever available). The partnership activity in this domain has been analyzed on the basis of the year of establishment of the company, the type of partnership model employed, the companies involved, therapy type and prominent product candidates involved.

Chapter 13 provides details on the various investments and grants awarded to players focused on the development of T-cell immunotherapies. The analysis highlights the growing interest of the VC community and other strategic investors in this domain.

Chapter 14 offers details of other novel T-cell based technologies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. We have provided a brief overview of these upcoming therapies, along with details of their mechanisms of action and the process followed for dose administration.

Chapter 15 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For these players, we have included details, such as the scale of operation, compliance to cGMP standards, location of various manufacturing facilities and the products being manufactured.

Chapter 16 highlights our view point on the various factors that must be considered while pricing the cell based therapies. It features discussions on different models / approaches that a pharmaceutical company can follow to decide the price at which their T-cell based immunotherapy product is likely to be marketed.

Chapter 17 includes detailed company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes information such as financial performance, geographical presence, T-cell immunotherapy pipeline, collaborations and recent developments. Additionally, we have also provided details of the strategic / venture capital investments made in these companies.

Chapter 18 is a collection of transcripts of interviews conducted during the course of this study. In this chapter, we have presented the details of our conversations with Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Director, Process Development, Lion Biotechnologies), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma) and Miguel Forte (Chief Operating Officer, TxCell).

Chapter 19 summarizes the entire report. Here, we have provided a list of key takeaways and our independent opinion on the current state and future opportunity in this field.

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 21 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report.

1. AbbVie
2. Abingworth
3. Abraxis BioScience
4. AbVitro
5. Adaptimmune
6. Adicet Bio
7. Advanced BioScience Laboratories
8. Adverum Biotechnologies
9. Affiliated Hospital to Academy of Military Medical Sciences
10. AGF Private Equity
11. AgonOx
12. Agreen Biotech
13. AJU IB Investment
14. Alaska Permanent Fund
15. Albert Einstein College of Medicine
16. Alexandria Ventures
17. Alexion Pharmaceuticals
18. Allen Laboratories
19. Allos Therapeutics
20. Alpine Immune Sciences
21. Alta Partners
22. Altor BioScience
23. Amgen
24. Amsterdam BioTherapeutics Unit
25. Antoni van Leeuwenhoek Hospital
26. apceth Biopharma
27. Aquilo Capital Management
28. ARCH Venture Partners
29. Argos Therapeutics
30. Artax BioPharma
31. Astellas Pharma
32. AstraZeneca
33. Asymptote
34. Atara Biotherapeutics
35. Atlantic Bio GMP
36. Atlas Venture
37. Atreca Therapeutics
38. AURORA BioPharma
39. Autolus
40. AVG Ventures
41. Avidex
42. BankInvest Biomedical Venture
43. Batavia Biosciences
44. Bavarian Nordic
45. Baxalta
46. Bayer
47. Bayer Crop Sciences
48. Baylor College of Medicine
49. Beijing Doing Biomedical
50. Bellicum Pharmaceuticals
51. Bezos Expeditions
52. Bill & Melinda Gates Foundation
53. Bio Elpida
54. Biogen
55. BioLife Solutions
56. Biomedical Catalyst
57. Biomedical Catalyst Fund
58. BioNTech
59. Biotecnol
60. BioVeda China Fund
61. bluebird bio
62. Boehringer Ingelheim
63. Boston Children's Hospital
64. Bpifrance
65. Brace Pharma Capital
66. Breast International Group
67. Bristol-Myers Squibb
68. Broad Institute
69. Broadfin Capital
70. Cabaret Biotech
71. Caladrius Biosciences
72. California Institute for Regenerative Medicine
73. Cancer Prevention and Research Institute of Texas
74. Cancer Research UK
75. Cardiff University
76. Caribou Biosciences
77. CARsgen Therapeutics
78. Cartherics
79. Casdin Capital
80. Celgene
81. Cell and Gene Therapy Catapult
82. Cell Design Labs
83. Cell Medica
84. Cell Therapies
85. Cell Therapy and Cell Engineering Facility
86. Cellectis
87. CELLforCURE
88. Cellular Biomedicine Group
89. Cellular Therapeutics
90. Celyad
91. Centre for Cell Manufacturing Ireland
92. Changzheng Hospital
93. Charité - Universitätsmedizin Berlin
94. CHDI Foundation
95. Chengdu MedGenCell
96. Children's Hospital of Philadelphia
97. Children's Mercy Hospital Kansas City
98. Chimeric Therapeutics
99. Chinese PLA General Hospital
100. Christie NHS Foundation Trust
101. Chugai Seiyaku Kabushiki Kaisha
102. City of Hope Medical Center
103. Clough Capital Partners
104. Cognate Bioservices
105. Cold Genesys
106. Columbia University
107. Cooperative Research Center for Cell Therapy Manufacturing
108. Corixa
109. Cowen Group Investment
110. CRISPR Therapeutics
111. Cystic Fibrosis Foundation Therapeutics
112. Cytolumina Technologies
113. Cytovance Biologics
114. Dana-Farber Cancer Institute
115. Dangdai International
116. Dartmouth College
117. Deerfield Management
118. Delenex Therapeutics
119. Dendreon
120. Duke University
121. Dutch Cancer Society
122. Easton Capital
123. EcoR1 Capital
124. Editas Medicine
125. Edmond Venture Capital
126. Eisai
127. Eli Lilly
128. Endocyte
129. Erasmus University Medical Center
130. ERS Genomics
131. EUFETS
132. Eureka Therapeutics
133. Fate Therapeutics
134. FCB-Pharmicell
135. Fetolumina Technologies
136. FGP Capital
137. Fidelity Biosciences
138. Fidelity Management & Research Company
139. Financière IDAT
140. Finnish Innovation Fund
141. Five Prime Therapeutics
142. Flagship Ventures
143. Fondazione Telethon
144. Forbion Capital Partners
145. Foresite Capital
146. Formula Pharmaceuticals
147. Fortress Biotech
148. Franklin Templeton Investments
149. Fraunhofer Insitute for Cell Therapy and Immunology
150. Fred Hutchinson Cancer Research Center
151. Fuda Cancer Hospital
152. Gadeta
153. GammaCell Bio-Technologies
154. GE Global Research
155. Gene and Cell Therapy Lab
156. Genentech
157. Généthon
158. GigaGen
159. Gilead Sciences
160. GlaxoSmithKline
161. Google Ventures
162. Great Ormond Street Hospital
163. Green Cross Cell
164. Griffin Securities
165. Guy's and St Thomas' NHS Foundation Trust
166. H. Lee Moffitt Cancer Center and Research Institute Hospital
167. Hadassah Medical Organization
168. Harvard University
169. Heat Biologics
170. Herlev Hospital
171. Howard Hughes Medical Institute
172. iCarTAB BioMed
173. iCell Therapeutics
174. ImClone Systems
175. Immatics
176. Immune Therapeutics
177. Immunex
178. ImmunoCellular Therapeutics
179. Immunocore
180. Immunovative Therapies
181. Imperial College London
182. Imperial Innovations
183. Innovative Cellular Therapeutics
184. Innovative Genome Initiative
185. Institut Curie (Curie Institute)
186. Institut Pasteur (Pasteur Institute)
187. Institute of Translational Health Sciences
188. Intellia Therapeutics
189. Intrexon
190. Iowa State University
191. Janssen Biotech
192. Janus Capital Group
193. JCR Pharmaceutical
194. Jennison Associates
195. JIC GenesisFountain Healthcare Ventures
196. Jichi Medical University Hospital
197. JMP Securities
198. John Wayne Cancer Institute
199. Johns Hopkins Kimmel Cancer Center
200. Johns Hopkins University
201. Johnson & Johnson
202. Jolly Innovation Ventures
203. Juno Therapeutics
204. JW Biotechnology
205. Kaitai Capital
206. Karolinska University Hospital
207. Keio University School of Medicine
208. Khosla Ventures
209. King's College London- Rayne Cell Therapy Suite
210. Kite Pharma
211. KTB Ventures
212. Leiden University Medical Center
213. Leucid Bio
214. Lifeline Ventures Fund
215. Ligand Pharmaceuticals
216. Lilly Asia Ventures
217. Lion Biotechnologies
218. Lion TCR
219. Lonza Biologics
220. Loyola University
221. Lymphoma and Leukemia Society
222. MabQuest
223. Malin Corporation
224. Massachusetts General Hospital
225. MaSTherCell
226. Max Delbrück Center for Molecular Medicine
227. MaxCyte
228. Mayo Clinic
229. MD Anderson Cancer Center
230. Medarex
231. Medicxi Ventures
232. Medigene
233. MedImmune
234. MedPost Urgent Care
235. Memorial Sloan Kettering Cancer Center
236. Merck
237. Merck Serono
238. Merlin Nexus
239. Mie University
240. Millennium Pharmaceuticals
241. Miltenyi Biotec
242. Mission Bay Capital
243. Molecular and Cellular Therapeutics
244. MolMed
245. Morphotek
246. Mustang Bio
247. Nantes University Hospital
248. NantKwest (earlier Conkwest)
249. NantWorks
250. National Cancer Institute
251. National Institute of Allergy and Infectious Diseases
252. National Institutes of Health
253. National University of Ireland
254. National University of Singapore
255. Netherlands Cancer Institute
256. New Enterprise Associates
257. New Leaf Venture Partners
258. New River Management
259. NewVa Capital Partners
260. NIHR Oxford Biomedical Research Centre
261. Novartis
262. Novartis Venture Fund
263. Novo Ventures
264. Oberland Capital
265. ODYSSEE Venture
266. Ohio State University
267. Omega Funds
268. Oncodesign Biotechnology
269. OnCyte
270. ONO Pharmaceutical
271. Onyx Pharmaceuticals
272. Opexa Therapeutics
273. Opus Bio
274. OrbiMed
275. OSEO
276. Ospedale Pediatrico Bambino Gesù (Bambino Gesù Children’s Hospital)
277. Ospedale San Raffaele (San Raffaele Hospital)
278. Oxford BioMedica
279. Partners Innovation Fund
280. Peking University
281. Perceptive Bioscience Investments
282. PersonGen Biomedicine (Suzhou)
283. Peter MacCallum Cancer Centre
284. Pfizer
285. PharmaCell
286. Pharmacyclics
287. Pierre Fabre Group
288. PLA General Hospital
289. Polaris Partners
290. PolyBioCept
291. Pontifax
292. Poseida Therapeutics
293. Precision BioSciences
294. Pregenen
295. Progenitor Cell Therapy
296. Prometheus Laboratories
297. QueensBridge Venture Partners
298. Quogue Capital
299. QVT Financial
300. RA Capital Management
301. Ramius Capital Group
302. Redmile Group
303. RedoxTherapies
304. Regeneron Pharmaceuticals
305. Remeditex Ventures
306. Renji Hospital
307. Ridgeback Capital Management
308. Ridgeway Capital Partners
309. Riverbank Capital Securities
310. Roche
311. Rock Springs Capital
312. Rockland Immunochemicals
313. Roger Williams Medical Center
314. Roswell Park Cancer Institute
315. Royal Adelaide Hospital Cancer Center
316. Sabby Management
317. Sanford Research
318. Sangamo BioSciences
319. Sanofi Aventis
320. Sanofi-Genzyme BioVentures
321. Schering-Plough
322. Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility
323. Seattle Children’s Hospital
324. Seattle Genetics
325. Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
326. Second Military Medical University
327. Sectoral Asset Management
328. Servier
329. Shanghai Cancer Institute
330. Shanghai Chest Hospital
331. Shanghai Genechem
332. Sheba Medical Center
333. Shenzhen Institute for Innovation and Translational Medicine
334. Shenzhen Second People's Hospital
335. Shionogi
336. Sichuan University
337. Sidney Kimmel Comprehensive Cancer Center
338. Sinobioway Cell Therapy
339. SOLTI Breast Cancer Research Group
340. Sorrento Therapeutics
341. SOTIO
342. Southwest Hospital
343. Spectrum Pharmaceuticals
344. SR One
345. St. Jude Children's Research Hospital
346. Stage Cell Therapeutics
347. Stanford University
348. Stifel
349. Sun Yat-Sen University
350. Super-T Cell Cancer Company
351. Syncona
352. T. Rowe Price Associates
353. Takara Biosciences
354. Targazyme
355. T-Cell Factory
356. Techno Venture Management
357. Tel Aviv Sourasky Medical Center
358. Terumo
359. Tessa Therapeutics
360. Tethys Holdings
361. Texas Emerging Technology Fund
362. The Clinical Cell and Vaccine Production Facility
363. Theravectys
364. Thermo Fisher Scientific
365. Third Military Medical University
366. Third Rock Ventures
367. Third Security
368. Three Arch Opportunity Fund
369. Tianjin Medical University Cancer Institute and Hospital
370. TiGenix
371. TILT Biotherapeutics
372. Tmunity Therapeutics
373. TNK Therapeutics
374. Tongji Hospital
375. Tongji University School of Medicine
376. TRACT Therapeutics
377. Transposagen Biopharmaceuticals
378. Triumvira Immunologics
379. TVAX Biomedical
380. TVM Capital
381. Two Blades Foundation
382. TxCell
383. UCLA Jonsson Comprehensive Cancer Center
384. UNC Lineberger Comprehensive Cancer Center
385. uniQure
386. United Therapeutics
387. Universal Cells
388. University College London
389. University Health Network, Toronto
390. University Medical Center Utrecht
391. University of Birmingham
392. University of California, Berkeley
393. University of Florida
394. University of Lausanne
395. University of Milano-Bicocca
396. University of Minnesota
397. University of Oxford
398. University of Pennsylvania
399. University of Zurich
400. Unum Therapeutics
401. Uppsala University
402. Utrecht Holdings
403. Vaccinogen
404. Valeant Pharmaceuticals
405. venBio
406. Venrock
407. Versant Ventures
408. Vertex
409. VGXI
410. Vical
411. Viking Global Investors
412. ViroMed
413. Vor Biopharma
414. Weill Cornell Graduate School of Medical Sciences
415. Wellington Management
416. West China Hospital
417. Woodford Investment Management
418. Wunderlich
419. WuXi AppTec
420. Wyeth (Pfizer)
421. X-Body
422. Xijing Hospital
423. Xinqiao Hospital
424. Xuzhou Medical College
425. Zhujiang Hospital
426. ZIOPHARM Oncology


1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining a Strong Foothold
3.4. Immuno-Oncology: Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Cell Based Therapies
3.6. T-Cell Immunotherapy: Historical Evolution
3.7. T-Cell Immunotherapy: Key Considerations
3.8. Strategies Employed for Redirection of T-Cells
3.9. T-Cell Transduction / Transfection Methods
3.9.1. Retroviral Vectors
3.9.2. Lentiviral Vectors
3.9.3. Non-viral Transfection Methods
3.9.3.1. Sleeping Beauty Transposon
3.10. T-Cell Immunotherapy: Targeted Therapeutic Areas
3.11. T-Cell Immunotherapy: Key Challenges
4. Market Landscape
4.1. Chapter Overview
4.2. T-Cell Immunotherapy: An Evolving Landscape
4.3. T-Cell Immunotherapy: A Promising Pipeline
4.3.1. T-Cell Immunotherapy: CAR-T Cells
4.3.1.1. Clinical Pipeline
4.3.1.2. Preclinical / Discovery Pipeline
4.3.2. T-Cell Immunotherapy: TCR Cells
4.3.2.1. Clinical Pipeline
4.3.2.2. Preclinical / Discovery Pipeline
4.3.3. T-Cell Immunotherapy: TIL Cells
4.3.3.1. Clinical Pipeline
4.3.3.2. Preclinical / Discovery Pipeline
4.4. T-Cell Immunotherapy: Distribution of Candidate Therapies by Type of Product
4.5. T-Cell Immunotherapy: Distribution of Candidate Therapies by Type of Developer
4.6. T-Cell Immunotherapy: Distribution of Candidate Therapies by Phase of Development
4.7. T-Cell Immunotherapy: Target Oncological Indications
4.7.1. CAR-T Cell Immunotherapy: Popular Target Indications
4.7.2. TCR Cell Immunotherapy: Popular Target Indications
4.7.3. TIL Cell Immunotherapy: Popular Target Indications
4.8. T-Cell Immunotherapy: Key Industry Players
4.9. T-Cell Immunotherapy: Key Non-Industry Players
4.10. T-Cell Immunotherapy: Most Popular Targets for CAR-T and TCR Therapies
5. Chimeric Antigen Receptor-T (CAR-T) Cell Therapy
5.1. Introduction
5.2. History of Development
5.3. Key Opinion Leaders
5.4. Anatomical Layout of Chimeric Antigen Receptor
5.5. Development of Chimeric Antigen Receptors
5.6. Development of CAR-T Cells
5.7. Universal CAR-Ts
5.8. Route of Administration
5.9. Toxicity Issues
5.9.1. Cytokine Release Syndrome (CRS)
5.9.2. On-Target Off-Tumor Toxicity
5.9.3. Encephalopathy and B-Cell Aplasia
5.10. Management of Toxicity Issues
5.10.1. Target Selection
5.10.2. Cell Persistence
5.10.3. Receptor Expression
5.11. CD19: An Attractive Target
5.12. Other Targets
5.13. Challenges Associated with CAR-T Therapy
5.13.1. Competitive Risks
5.13.2. Clinical Risks
5.13.3. Regulatory Risks
5.13.4. Commercial Risks
5.14. CTL019 (Novartis)
5.14.1. Introduction
5.14.2. History of Development
5.14.3. Development Status
5.14.4. Key Clinical Trial Results
5.14.4.1. Acute Lymphoblastic Leukemia
5.14.4.2. Non-Hodgkin’s Lymphoma
5.14.4.3. Chronic Lymphocytic Leukemia
5.14.4.4. Multiple Myeloma
5.14.5. Dosage Regimen, Treatment Cost and Manufacturing
5.15. JCAR (Juno Therapeutics)
5.15.1. Introduction
5.15.2. CAR-T Design
5.15.3. Development Status
5.15.4. Key Clinical Trial Results
5.15.4.1. JCAR014
5.15.4.2. JCAR015
5.15.4.3. JCAR017
5.15.4.4. JCAR018
5.15.5. Dosage Regimen and Manufacturing
5.16. KTE-C19 (Kite Pharma)
5.16.1. Introduction
5.16.2. Development Status
5.16.3. Key Clinical Trial Results
5.16.3.1. Non-Hodgkin’s Lymphoma
5.16.3.2. Acute Lymphoblastic Leukemia
5.16.4. Dosage Regimen and Manufacturing
5.16.5. Next Generation eACT CAR Candidates
5.17. CAR-T Series (Cellular Biomedicine Group)
5.17.1. Introduction
5.17.2. History of Development
5.17.3. Development Status
5.17.4. Key Clinical Trial Results
5.17.4.1. CBM-EGFR.1
5.17.4.2. CBM-C19.1
5.17.4.3. CBM-C20.1
5.17.4.4. CBM-C30.1
5.17.5. Dosage Regimen, Manufacturing and Patent Portfolio
5.18. CD19 CAR (Takara Bio)
5.18.1. Introduction
5.18.2. Development Status
5.18.3. Key Clinical Trial Results
5.18.4. Dosage Regimen and Manufacturing
6. T-Cell Receptor (TCR) Based Therapies
6.1. Introduction
6.2. Structure of the T-Cell Receptor
6.3. Difference between CAR and TCR
6.4. History of Development
6.5. Key Opinion Leaders
6.6. Mechanism of Action
6.7. Safety Issues
6.7.1. Insertional Mutagenesis
6.7.2. On-Target Off-Tumor Toxicity and Cross-Reactivity
6.7.3. TCR Mismatch Pairing
6.8. Prerequisites of Antigen-Specific T-Cell Receptors
6.9. Identifying Strategies that Enhance Antitumor Efficacy
6.9.1. Affinity Enhanced TCRs
6.9.2. Soluble TCR Based Biologics
6.10. SPEAR T-Cells (Adaptimmune)
6.10.1. Introduction
6.10.1.1. NY-ESO SPEAR T-Cell
6.10.1.2. Mage-A10 T-Cell Therapy
6.10.1.3. AFP T-Cell therapy
6.10.2. History of Development
6.10.3. SPEAR T-cells Technology Platform
6.10.4. Development Status
6.10.5. Key Clinical Trial Results
6.10.5.1. Multiple Myeloma
6.10.5.2. Synovial Sarcoma
6.10.5.3. Ovarian Cancer
6.10.5.4. Multiple Myeloma, Synovial Sarcoma and Ovarian Cancer: Combined Results
6.10.6. Dosage Regimen and Manufacturing Information
6.11. ALT-801 (Altor BioScience)
6.11.1. Introduction
6.11.2. History of Development
6.11.3. Development Status
6.11.4. Key Clinical Trial Results
6.11.4.1. Urothelial Carcinoma
6.11.4.2. Bladder Cancer
6.11.5. Dosage Regimen and Patent Portfolio
6.12. IMCgp100 (Immunocore)
6.12.1. Introduction
6.12.2. Development Status
6.12.3. Key Clinical Trial Results
6.12.4. Dosage Regimen
6.13. JTCR016 (Juno Therapeutics)
6.13.1. Introduction
6.13.2. Development Status
6.13.3. Key Clinical Trial Results
6.13.4. Dosage Regimen
6.14. WT1 TCR Gene Therapy (Cell and Gene Therapy Catapult)
6.14.1. Introduction
6.14.2. History of Development
6.14.3. Development Status
6.14.4. Key Clinical Trial Results
6.14.5. Dosage Regimen and Manufacturing
7. Tumor Infiltrating Lymphocytes (TIL) Based Therapies
7.1. Introduction
7.2. History of Development
7.3. Key Opinion Leaders
7.4. Research Strategies to Enhance Efficacy
7.5. A Prognostic Tool
7.6. Manufacturing Process
7.7. LN-144 (Lion Biotechnologies)
7.7.1. Introduction
7.7.2. Development Status
7.7.3. Key Clinical Trial Results
7.7.4. Dosage Regimen and Manufacturing
7.7.5. Patent Portfolio
7.7.6. Next-Generation TILs
7.8. TIL (Nantes University Hospital)
7.8.1. Introduction
7.8.2. Development Status
7.8.3. Key Experimental Results
7.8.4. Dosage Regimen and Manufacturing
7.9. TIL (Netherlands Cancer Institute)
7.9.1. Introduction
7.9.2. Development Status
7.9.3. Key Clinical Trial Results
7.9.4. Dosage Regimen and Manufacturing
8. Market Opportunity
8.1. Chapter Overview
8.2. Scope and Limitations
8.3. Forecast Methodology
8.4. Overall T-Cell Immunotherapy Market (Till 2030)
8.5. Overall Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Market
8.5.1. CTL019 (Novartis)
8.5.1.1. Target Population
8.5.1.2. Sales Forecast (Till 2030)
8.5.2. KTE-C19 (Kite Pharma)
8.5.2.1. Target Population
8.5.2.2. Sales Forecast (Till 2030)
8.5.3. JCAR015 (Juno Therapeutics)
8.5.3.1. Target Population
8.5.3.1.1. Sales Forecast (Till 2030)
8.5.4. CBM-CD30 CAR-T (Cellular Biomedicine Group)
8.5.4.1. Target Population
8.5.4.2. Sales Forecast (Till 2030)
8.5.5. CBM-CD20 CAR-T (Cellular Biomedicine Group)
8.5.5.1. Target Population
8.5.5.2. Sales Forecast (Till 2030)
8.5.6. CBM-EGFR.1 CAR-T (Cellular Biomedicine Group)
8.5.6.1. Target Population
8.5.6.2. Sales Forecast (Till 2030)
8.5.7. CD 19 CAR-T (Sinobioway Cell Therapy)
8.5.7.1. Target Population
8.5.7.2. Sales Forecast (Till 2030)
8.5.8. CD 19 CAR-T (Takara Bio)
8.5.8.1. Target Population
8.5.8.2. Sales Forecast (Till 2030)
8.5.9. GPC3 CAR-T (Shanghai Genechem)
8.5.9.1. Target Population
8.5.9.2. Sales Forecast (Till 2030)
8.5.10. JCAR017 (Juno Therapeutics)
8.5.10.1. Target Population
8.5.10.2. Sales Forecast (Till 2030)
8.6. Overall TCR Market (Till 2030)
8.6.1. IMCgp100 (Immunocore)
8.6.1.1. Target Population
8.6.1.2. Sales Forecast (Till 2030)
8.6.2. HPV-16E6-TCR (Kite Pharma)
8.6.2.1. Target Population
8.6.2.2. Sales Forecast (Till 2030)
8.6.3. NY-ESO-1 TCR (Adaptimmune)
8.6.3.1. Target Population
8.6.3.2. Sales Forecast (Till 2030)
8.6.4. HBV antigen specific TCR redirected T-Cell (Lion TCR)
8.6.4.1. Target Population
8.6.4.2. Sales Forecast (Till 2030)
8.6.5. ALT-801 (Altor BioScience)
8.6.5.1. Target Population
8.6.5.2. Sales Forecast (Till 2030)
8.6.6. JTCR016 (Juno Therapeutics)
8.6.6.1. Target Population
8.6.6.2. Sales Forecast (Till 2030)
8.6.7. KITE-718 (MAGE A3/A6) (Kite Pharma)
8.6.7.1. Target Population
8.6.7.2. Sales Forecast (Till 2030)
8.6.8. MAGE A3 (Kite Pharma)
8.6.8.1. Target Population
8.6.8.2. Sales Forecast (Till 2030)
8.6.9. WT-1 TCR (Cell Therapy Catapult)
8.6.9.1. Target Population
8.6.9.2. Sales Forecast (Till 2030)
8.6.10. MAGE A-10 TCR (Adaptimmune)
8.6.10.1. Target Population
8.6.10.2. Sales Forecast (Till 2030)
8.7. Overall TIL Therapy Market (Till 2030)
8.7.1. LN-144 (Lion Biotechnologies)
8.7.1.1. Target Population
8.7.1.2. Sales Forecast (Till 2030)
8.7.2. TIL Therapy (Nantes University)
8.7.2.1. Target Population
8.7.2.2. Sales Forecast (Till 2030)
8.7.3. TIL Therapy (Netherlands Cancer Institute)
8.7.3.1. Target Population
8.7.3.2. Sales Forecast (Till 2030)
9. Key Therapeutic Areas for T-Cell Therapies
9.1. Chapter Overview
9.2. Introduction
9.3. Hematological Malignancies
9.3.1. Leukemia and Lymphoma
9.3.1.1. Leukemia: Introduction and Epidemiology
9.3.1.1.1. Acute Myeloid Leukemia (AML)
9.3.1.1.2. Chronic Myeloid Leukemia (CML)
9.3.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.3.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.3.1.2. Lymphoma: Introduction and Epidemiology
9.3.1.3. Current Treatment Landscape
9.3.1.3.1. Targeted Therapies
9.3.1.4. T-Cell Immunotherapy and Research Landscape
9.3.1.4.1. CAR-Ts and Leukemia / Lymphoma
9.3.1.4.2. TCRs and Leukemia / Lymphoma
9.3.2. Multiple Myeloma
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. T-Cell Immunotherapy and Research Landscape
9.4. Solid Tumors
9.4.1. Metastatic Melanoma
9.4.1.1. Introduction and Epidemiology
9.4.1.2. Current Treatment Landscape
9.4.1.3. T-Cell Immunotherapy and Research Landscape
9.4.1.3.1. TILs and Metastatic Melanoma
9.4.1.3.1.1. TIL Research at the MD Anderson Cancer Center, US
9.4.1.3.1.2. TIL Research at the Sheba Medical Centre, Israel
9.4.1.3.2. TCRs and Metastatic Melanoma
9.4.1.3.3. CAR-Ts and Metastatic Melanoma
9.4.2. Lung Cancer
9.4.2.1. Introduction and Epidemiology
9.4.2.2. Current Treatment Landscape
9.4.2.3. T-Cell Immunotherapy and Research Landscape
9.4.3. Bladder Cancer
9.4.3.1. Introduction and Epidemiology
9.4.3.2. Current Treatment Landscape
9.4.3.3. T-Cell Immunotherapy and Research Landscape
9.4.4. Kidney Cancer
9.4.4.1. Introduction and Epidemiology
9.4.4.2. Current Treatment Landscape
9.4.4.3. T-Cell Immunotherapy and Research Landscape
9.4.5. Ovarian Cancer
9.4.5.1. Introduction and Epidemiology
9.4.5.2. Current Treatment Landscape
9.4.5.3. T-Cell Immunotherapy and Research Landscape
9.4.5.3.1. CAR-Ts and Ovarian Cancer
9.4.6. Breast Cancer
9.4.6.1. Introduction and Epidemiology
9.4.6.2. Current Treatment Landscape
9.4.6.3. T-Cell Immunotherapy and Research Landscape
9.4.6.3.1. CAR-Ts and Breast Cancer
9.4.6.3.2. TILs and Breast Cancer
10. Emerging Technologies
10.1. Chapter Overview
10.2. Introduction
10.3. Genome Editing Technologies: Introduction
10.4. Genome Editing Technologies: Applications
10.4.1. Genome Editing Technologies: Emerging Technology Platforms Used in T-Cell Therapies
10.4.1.1. CRISPR/Cas9 System
10.4.1.1.1. Key Components and Function
10.4.1.1.2. Mechanism of Action
10.4.1.1.3. Targeting Efficiency and Challenges
10.4.1.1.4. Next-GEN CRISPR Technology
10.4.1.1.5. Technology Providers
10.4.1.1.5.1. Editas Medicine
10.4.1.1.5.2. Intellia Therapeutics
10.4.1.1.5.3. CRISPR Therapeutics
10.4.1.2. TALENs
10.4.1.2.1. Structural Features
10.4.1.2.2. Mechanism of Action
10.4.1.2.3. Advantages and Challenges
10.4.1.2.4. Technology Providers
10.4.1.2.4.1. Cellectis
10.4.1.2.4.2. Editas Medicine
10.4.1.3. megaTAL
10.4.1.3.1. Technology Providers
10.4.1.3.1.1. bluebird bio
10.4.1.4. Zinc Finger Nuclease
10.4.1.4.1. Technology Providers
10.4.1.4.1.1. Sangamo Biosciences
10.5. Designing T-Cell Therapies with Improved Characteristics
10.5.1. Technology for Targeting Multiple Cancers
10.5.1.1. Antibody Coupled T-Cell Receptor, Unum Therapeutics
10.5.1.2. NKR-T Platform, Celyad
10.5.2. Technology For Improved Safety
10.5.2.1. Armored CAR, Juno Therapeutics
10.5.2.2. RheoSwitch Therapeutic System, Intrexon
10.5.2.3. Inducible Caspase 9 Safety Switch, Bellicum Pharmaceuticals
10.5.2.3.1. CaspaCIDe Technology
10.5.2.3.2. CIDeCAR Technology
10.5.2.3.3. GoCAR-T Technology
10.5.2.4. On-Off Switch, Multiple Companies
10.5.2.4.1. Inhibitory CAR (iCAR), Juno Therapeutics
10.5.2.4.2. On-Off Switch, Theravectys
10.5.2.5. Allogeneic Technology
10.5.2.5.1. CIK CAR-T Cells, Formula Pharmaceuticals
10.5.2.5.2. Allogeneic Platform, Celyad
10.5.2.5.3. Allogeneic Platform, Cellectis
11. Social Media: Emerging Trends
11.1. Chapter Overview
11.2. Trends on Twitter
11.2.1. Yearly Trends on Twitter
11.2.2. Popular Keywords on Twitter
11.2.3. Most Popular Drugs on Twitter
12. Partnerships and Collaborations
12.1. Chapter Overview
12.2. Partnership Models
12.3. Recent Collaborations
12.3.1. Distribution of Partnerships by Year
12.3.2. Distribution of Partnerships by Type of Model
12.3.3. Leading Industry Collaborators
12.3.4. Leading Non-Industry Collaborators
12.3.5. Distribution of Partnerships by Type of Therapy
12.3.6. Distribution of Partnerships by Product Therapy
13. Venture Capital Support
13.1. Chapter Overview
13.2. T-Cell Immunotherapy: List of Funding Instances
13.2.1. T-Cell Immunotherapy: Funding Instances, Cumulative Number of Funding Instances by Year, pre-2009-2016
13.2.2. T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016
13.2.3. T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
13.2.4. T-Cell Immunotherapy: Funding Instances, Distribution of Amount Invested by Type of Funding
14. Other T-Cell Immunotherapies
14.1. Chapter Overview
14.2. Other T-Cell Immunotherapies
14.2.1. Treg Cell Therapy
14.2.1.1. Caladrius Biosciences
14.2.1.2. TxCell
14.2.1.3. TRACT Therapeutics
14.2.1.4. Other Companies
14.2.2. T-Cell Based Vaccines
14.2.2.1. Immunovative Therapies
14.2.2.2. Opexa Therapeutics
14.2.2.3. TVAX
14.2.3. Virus-Driven T-Cell Therapies
14.2.3.1. Atara Biotherapeutics
14.2.3.2. Cell Medica
14.2.3.3. Tessa Therapeutics
14.2.4. Fucosylation Technology Platform
14.2.4.1. Targazyme
14.2.5. PD-1 Knockout Engineered T-Cells
14.2.5.1. Chengdu MedGenCell
14.2.6. TAC-T Cells
14.2.6.1. Triumvira
14.2.7. Vγ9δ2 T cell T-Cell immunotherapy
14.2.7.1. GammaCell Biotechnologies
15. Case Study: Cell Therapy Manufacturing
15.1. Chapter Overview
15.2. Introduction
15.3. Key Challenges
15.4. Current Trends
15.4.1. Companies with In-house Capabilities
15.4.2. Contract Manufacturers
15.5. Key Considerations for a Manufacturing Site
15.6. Regulatory Landscape
16. T-Cell Immunotherapy: Cost Price Analysis
16.1. Chapter Overview
16.2. Cell / Gene Therapies: Factors Contributing Towards Higher Price Tags
16.3. T-Cell Immunotherapy: Pricing Models
16.3.1. Pricing Model: Based On Associated Costs
16.3.2. Pricing Model: Based On Competition
16.3.3. Pricing Model: Based on Expert Opinions
17. Company Profiles
17.1. Chapter Overview
17.2. Adaptimmune
17.2.1. Company Overview
17.2.2. Financial Information
17.2.3. Product Portfolio
17.2.4. Manufacturing Capabilities
17.2.5. Collaborations
17.2.5.1. Immunocore
17.2.5.2. Progenitor Cell Therapy
17.2.5.3. Thermo Fisher Scientific
17.2.5.4. GlaxoSmithKline
17.2.5.5. Universal Cells
17.2.5.6. MD Anderson Cancer Center
17.2.5.7. Merck
17.2.5.8. Bellicum Pharmaceuticals
17.2.6. Future Outlook
17.3. Altor BioScience
17.3.1. Company Overview
17.3.2. Financial Performance
17.3.3. Product Portfolio
17.3.4. Patent Portfolio
17.3.5. Collaborations
17.3.5.1. Massachusetts General Hospital and Howard Hughes Medical Institute
17.3.5.2. National Cancer Institute (NCI)
17.3.5.3. NantKwest
17.3.6. Future Outlook
17.4. bluebird Bio
17.4.1. Company Overview
17.4.2. Financial Performance
17.4.3. Product Portfolio
17.4.4. Collaborations
17.4.4.1. Celgene Corporation
17.4.4.2. Baylor College of Medicine
17.4.4.3. Pregenen
17.4.4.4. Five Prime Therapeutics
17.4.4.5. Kite Pharma
17.4.4.6. ViroMed
17.4.5. Future Outlook
17.5. Cellectis
17.5.1. Company Overview
17.5.2. Financial Information
17.5.3. Product Portfolio
17.5.4. Collaborations
17.5.4.1. Servier
17.5.4.2. CELLforCURE
17.5.4.3. Pfizer
17.5.4.4. Oncodesign
17.5.4.5. Ohio University
17.5.4.6. Weill Cornell Medical College
17.5.4.7. The University of Texas MD Anderson Cancer Center
17.5.4.8. Takara Biosciences
17.5.4.9. MabQuest
17.5.5. Future Outlook
17.6. Cellular Biomedicine Group
17.6.1. Company Overview
17.6.2. Financial Information
17.6.3. Product Portfolio
17.6.4. Manufacturing Capabilities
17.6.5. Collaborations
17.6.5.1. Agreen Biotech
17.6.5.2 Chinese PLA General Hospital
17.6.6. Future Outlook
17.7. Immunocore
17.7.1. Company Overview
17.7.2. Financial Information
17.7.3. Product Portfolio
17.7.4. Collaborations
17.7.4.1. Cardiff University
17.7.4.2. Genentech
17.7.4.3. GlaxoSmithKline
17.7.4.4. Medimmune
17.7.4.5. Eli Lilly
17.7.4.6. CMC Biologics
17.7.5. Future Outlook
17.8. Juno Therapeutics
17.8.1. Company Overview
17.8.2. Financial Information
17.8.3. Product Portfolio
17.8.4. Litigations
17.8.5. Manufacturing Capabilities
17.8.6. Collaborations
17.8.6.1. Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Seattle Children’s Research Institute
17.8.6.2. Opus Bio
17.8.6.3. MedImmune/AstraZeneca
17.8.6.4. Stage Cell Therapeutics
17.8.6.5. Editas Medicine
17.8.6.6. Fate Therapeutics
17.8.6.7. X-Body
17.8.6.8. Celgene
17.8.6.9. AbVitro
17.8.6.10. Wuxi AppTec
17.8.6.11. RedoxTherapies
17.8.6.12. Eureka Therapeutics, Memorial Sloan Kettering Cancer Center
17.8.7. Future Outlook
17.9. Kite Pharma
17.9.1. Company Overview
17.9.2. Financial Information
17.9.3. Product Portfolio
17.9.4. Manufacturing Capabilities
17.9.5. Collaborations
17.9.5.1. National Cancer Institute / National Institutes of Health
17.9.5.2. Cabaret Biotech
17.9.5.3. NeoStem
17.9.5.4. Amgen
17.9.5.5. Tel Aviv Sourasky Medical Center
17.9.5.6. T-Cell Factory (TCF)
17.9.5.7. bluebird bio
17.9.5.8. Leukemia and Lymphoma Society
17.9.5.9. Netherlands Cancer Institute
17.9.5.10. Alpine Immune Sciences
17.9.5.11. GE Global Research
17.9.5.12. Leiden University Medical Center
17.9.5.13. Genentech
17.9.5.14. Cell Designs Labs
17.9.5.15. University of California
17.9.5.16. BioLife Solutions
17.9.6. Future Outlook
17.10. Lion Biotechnologies
17.10.1. Company Overview
17.10.2. Financial Information
17.10.3. Product Portfolio
17.10.4. Manufacturing Capabilities
17.10.5. Collaborations
17.10.5.1. Lonza
17.10.5.2. H. Lee Moffitt Cancer Center and Research Institute
17.10.5.3. National Cancer Institute
17.10.5.4. National Institutes of Health
17.10.5.5. WuXi AppTec
17.10.5.6. MedImmune
17.10.5.7. PolyBioCept
17.10.5.8. Karolinska University Hospital
17.10.6. Upcoming Products: Next Generation TILs
17.10.7. Future Outlook
17.11. Novartis
17.11.1. Company Overview
17.11.2. Financial Information
17.11.3. Product Portfolio
17.11.4. Patent Litigation
17.11.5. Manufacturing Capabilities
17.11.6. Collaborations
17.11.6.1. University of Pennsylvania
17.11.6.2. Oxford BioMedica
17.11.6.3. Intellia Therapeutics and Caribou Biosciences
17.11.7. Future Outlook
17.12. Takara Bio
17.12.1. Company Overview
17.12.2. Financial Information
17.12.3. Product Portfolio
17.12.4. Manufacturing Capabilities
17.12.5. Collaborations
17.12.5.1. Tianjin Medical University, Cancer Institute and Hospital
17.12.5.2. Memorial Sloan Kettering Cancer Center
17.12.5.3. Jichi Medical University Hospital
17.12.5.4. Cellectis
17.12.5.5. Mile University School of Medicines
17.12.6. Future Outlook
17.13. Unum Therapeutics
17.13.1. Company Overview
17.13.2. Financial Information
17.13.3. Product Portfolio
17.13.4. Collaborations
17.13.4.1. Seattle Genetics
17.13.5. Future Outlook
18. Interview Transcripts
18.1. Chapter Overview
18.2. Vincent Brichard, Vice President, Immuno-Oncology, Celyad
18.3. Peter Ho, Director, Process Development, Lion Biotechnologies
18.4. Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development, Theravectys
18.5. Adrian Bot, Vice President, Translational Sciences, Kite Pharma
18.6. Miguel Forte, Chief Operating Officer, TxCell
19. Conclusion
19.1. T-Cell Therapies Have Emerged as a Promising Segment of the Immunotherapy Market
19.2. Development Activity in the Domain is Led by Academic Institutes, Some of Which Have Collaborated with Industry Players
19.3. Hematological Malignancies and Solid Tumors are Currently the Major Target Indications
19.4. A Number of Novel Technological Platforms Have Emerged as Vital Enablers of Growth In This Market
19.5. A Significant Number of Strategic Alliances Have Been Forged in Order To Advance the Development of Different Product Candidates
19.6. Manufacturing Complexities and High Development Cost of These Therapies Necessitate Premium Pricing
19.7. Multiple Novel Types of Immunotherapies, Other Than CAR-T, TCR and TIL, are Expected to Emerge in The Mid-Long Run
19.8. Backed by a Progressive Pipeline and VC Support, the Market is Poised for Significant Growth
20. Appendix 1: Tabulated Data
21. Appendix 2: List of Companies and Organizations
LIST OF FIGURES
Figure 3.1 The Four Pillars of Cancer Therapy
Figure 3.2 Difference between Active and Passive Immunotherapies
Figure 3.3 Difference between Specific and Non-Specific Immunotherapies
Figure 3.4 3Es of the Immune System
Figure 3.5 Strategies Employed for the Redirection of T-Cells
Figure 3.6 T-Cell Immunotherapy: Target Therapeutic Areas
Figure 3.7 T-Cell Immunotherapy: Key Challenges
Figure 4.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
Figure 4.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
Figure 4.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
Figure 4.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
Figure 4.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development across CAR-T, TCR and TIL
Figure 4.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
Figure 4.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
Figure 4.8 T-Cell Immunotherapy Pipeline: Popular Target Indications
Figure 4.9 CAR-T Cell Immunotherapy: Popular Target Indications
Figure 4.10 TCR Cell Immunotherapy: Popular Target Indications
Figure 4.11 TIL Cell Immunotherapy: Popular Target Indications
Figure 4.12 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
Figure 4.13 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
Figure 4.14 T-Cell Immunotherapy Pipeline: Active Non-Industry Players
Figure 4.15 CAR-T Cell Therapy Pipeline: Distribution by Target Antigen
Figure 4.16 TCR Therapy Pipeline: Distribution by Target Antigen
Figure 5.1 Historical Timeline: Development of CAR-T cells
Figure 5.2 CAR-T Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 5.3 CAR-T: Structure and Domains
Figure 5.4 CAR-T: CAR Generations Layout
Figure 5.5 Development of CAR-T Cells
Figure 5.6 Challenges Associated with CAR-T Therapy
Figure 5.7 CTL019: Industry Sponsored Clinical Trial Design
Figure 5.8 CTL019: Non-Industry Sponsored Clinical Trial Design
Figure 5.9 JCAR Series: Industry Sponsored Clinical Trial Design
Figure 5.10 JCAR Series: Non-Industry Sponsored Clinical Trial Design
Figure 5.11 KTE-C19: Clinical Trial Design
Figure 5.12 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 5.13 Cellular Biomedicine’s CAR-T Series: Clinical Trial Design
Figure 5.14 Takara Bio’s CD19 CAR-T: Clinical Trial Design
Figure 6.1 TCR Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 6.2 TCR Cell Therapy: Development Process
Figure 6.3 NY-ESO TCR: Industry Sponsored Clinical Trial Design
Figure 6.4 MAGE A-10 TCR: Industry Sponsored Clinical Trial Design
Figure 6.5 ALT-801: Clinical Trial Design
Figure 6.6 IMCgp100: Clinical Trial Design
Figure 6.7 JTCR016: Clinical Trial Design
Figure 6.8 WT1 TCR: Clinical Trial Design
Figure 7.1 TIL Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 7.2 TIL Cell Therapy: Manufacturing Process
Figure 7.3 LN-144: Clinical Trial Design
Figure 7.4 Nantes University Hospital’s TIL Therapy: Clinical Trial Design
Figure 7.5 Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 7.6 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Design
Figure 8.1 Overall T-Cell Immunotherapy Market (Till 2030): Base Scenario (USD Billion)
Figure 8.2 T-Cell Therapy Market, 2020, 2025 and 2030: Base Scenario (USD Million)
Figure 8.3 Overall CAR-T Market Forecast (Till 2030): Base Scenario (USD Billion)
Figure 8.4 CTL019: Current Status by Highest Phase of Development
Figure 8.5 CTL019 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.6 KTE-C19: Current Status by Highest Phase of Development
Figure 8.7 KTE-C19 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.8 JCAR015 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.9 CBM-CD30 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.10 CBM-CD20 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.11 CBM-EGFR CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.12 Sinobioway Cell Therapy’s CD 19 CAR-T: Current Status by Highest Phase of Development
Figure 8.13 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.14 Takara Bio’s CD 19 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.15 GPC3 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.16 JCAR017 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.17 Overall TCR Market Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.18 IMCgp100 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.19 HPV-16E6-TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.20 NY-ESO-1 TCR: Current Status by Highest Phase of Development
Figure 8.21 NY-ESO-1 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.22 HBV antigen specific TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.23 ALT-801: Current Status by Highest Phase of Development
Figure 8.24 ALT-801 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.25 JTCR016: Current Status by Highest Phase of Development
Figure 8.26 JTCR016 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.27 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.28 MAGE A3 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.29 WT-1 TCR: Current Status by Highest Phase of Development
Figure 8.30 WT-1 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.31 MAGE A-10 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.32 Overall TIL Market Forecast (Till 2030): Base Scenario (USD Billion)
Figure 8.33 LN-144 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.34 TIL Therapy (Nantes University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.35 TIL Therapy (Netherlands Cancer Institute) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.1 Leukemia: Classification
Figure 9.2 Leukemia: Global Epidemiological Distribution
Figure 9.3 Lymphoma: Global Epidemiological Distribution
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5 Melanoma: Global Epidemiological Distribution
Figure 9.6 Lung Cancer: Classification
Figure 9.7 Lung Cancer: Global Epidemiological Distribution
Figure 9.8 Bladder Cancer: Global Epidemiological Distribution
Figure 9.9 Kidney Cancer: Global Epidemiological Distribution
Figure 9.10 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.11 Breast Cancer: Global Epidemiological Distribution
Figure 10.1 Genome Editing Technologies: Applications
Figure 10.2 Genome Editing Technologies: Emerging Technology Platforms Used in T-Cell Platforms
Figure 10.3 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 10.4 Properties of Enhanced T-Cell Platform
Figure 10.5 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 11.1 T-Cell Immunotherapy Social Media Analysis: Twitter Trends, January 2011-June 2016
Figure 11.2 T-Cell Immunotherapy Social Media Analysis: Highlights on Twitter, January 2011 - June 2016
Figure 11.3 T-Cell Immunotherapy Social Media Analysis: Twitter, Most Popular Candidates, January 2011 - June 2016
Figure 12.1 T-Cell Immunotherapy: Cumulative Distribution of Partnerships by Year, Pre-2011-2016
Figure 12.2 T-Cell Immunotherapy: Distribution of Partnerships by Type of Model
Figure 12.3 T-Cell Immunotherapy: Leading Industry Collaborators
Figure 12.4 T-Cell Immunotherapy: Leading Non-industry Collaborators
Figure 12.5 T-Cell Immunotherapy: Distribution of Partnerships by Type of Therapy
Figure 12.6 T-Cell Immunotherapy: Distribution of Partnerships by Product Therapy
Figure 13.1 T-Cell Immunotherapy: Funding Instances, Cumulative Number of Investments by Year, pre-2009-2016
Figure 13.2 T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016 (USD Million)
Figure 13.3 T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
Figure 13.4 T-Cell Immunotherapy: Funding Instances Distribution of Amount Invested by Type of Funding (USD Million)
Figure 14.1 Treg Cells: Functions
Figure 15.1 Cell Therapy Manufacturing: Key Steps
Figure 15.2 Cell Therapy Manufacturing: Scenarios
Figure 15.3 T-Cell Immunotherapy Manufacturing: Key Collaborations
Figure 17.1 Adaptimmune: Funding Instances (USD Million)
Figure 17.2 Altor Bioscience: Funding Instances (USD Million)
Figure 17.3 bluebird bio: Funding Instances (USD Million)
Figure 17.4 Cellectis: Funding Instances (USD Million)
Figure 17.5 CBMG: Funding Instances (USD Million)
Figure 17.6 Immunocore: Funding Instances (USD Million)
Figure 17.7 Juno Therapeutics: Funding Instances (USD Million)
Figure 17.8 Kite Pharma: Funding Instances (USD Million)
Figure 17.9 Lion Biotechnologies: Funding Instances (USD Million)
Figure 17.10 Novartis: Revenues 2011-9M 2016 (USD Billion)
Figure 17.11 Novartis: Distribution of Revenues by Operating Segments, 2015 (USD Billion)
Figure 17.12 Takara Bio: Revenues, 2011-2016 (JPY Billion)
Figure 17.13 Unum Therapeutics: Funding Instances (USD Million)
Figure 17.14 ACTR Technology: Treatment Process
Figure 19.1 T-Cell Immunotherapy Market Landscape: Industry Participants
Figure 19.2 T-Cell Immunotherapy Market Landscape: Non-industry Participants
Figure 19.3 T-Cell Immunotherapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Million)
LIST OF TABLES
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
Table 3.2 Retroviral Vectors: Salient Features
Table 3.3 Lentiviral Vectors: Salient Features
Table 4.1 CAR-T Cell Immunotherapy: Clinical Pipeline
Table 4.2 CAR-T Cell Immunotherapy: Preclinical / Discovery Pipeline
Table 4.3 TCR Cell Therapy: Clinical Pipeline
Table 4.4 TCR Cell Immunotherapy: Preclinical / Discovery Pipeline
Table 4.5 TIL Cell Immunotherapy: Clinical Pipeline
Table 4.6 TIL Cell Immunotherapy: Preclinical / Discovery Pipeline
Table 5.1 Key Characteristics of CAR-T cells
Table 5.2 Comparison Between 1st and 2nd Generation CARs
Table 5.3 Grading Criteria for CRS
Table 5.4 Safety Switches under Development for CART-T Therapy
Table 5.5 CD19 CAR-T Cells: Preclinical Results
Table 5.6 Other Targets under Clinical/Preclinical Studies for CAR-T Therapy
Table 5.7 CTL019: Clinical Studies
Table 5.8 CTL019: Clinical Trial Endpoints (ALL)
Table 5.9 CTL019: Clinical Trial Endpoints (CLL/MM/NHL)
Table 5.10 JCAR Series: Molecules in Clinical Development
Table 5.11 JCAR: CAR-T Design
Table 5.12 JCAR014: Current Status of Development
Table 5.13 JCAR015: Current Status of Development
Table 5.14 JCAR017: Current Status of Development
Table 5.15 JCAR018: Current Status of Development
Table 5.16 JCAR020: Current Status of Development
Table 5.17 JCAR023: Current Status of Development
Table 5.18 JCAR024: Current Status of Development
Table 5.19 JCAR Series: Clinical Trial Endpoints (Phase II)
Table 5.20 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 5.21 JCAR: Dosage Regimen
Table 5.22 KTE-C19: Clinical Studies
Table 5.23 KTE-C19: Clinical Trial Endpoints
Table 5.24 KTE-C19: ZUMA-1 Phase II Results (≥3 months Follow-Up)
Table 5.25 KTE-C19: ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
Table 5.26 CBM CAR-T Series: Clinical Products,
Table 5.27 CBM-CD19.1 CAR-T: Clinical Studies
Table 5.28 CBM-CD20 CAR-T: Clinical Status
Table 5.29 CBM-CD30.1 CAR-T: Clinical Status
Table 5.30 CBM-EGFR.1 CAR-T: Clinical Status
Table 5.31 Cellular Biomedicine’s CAR-T Series: Clinical Trial Endpoints
Table 5.32 CBM CAR-T Series: Patent Portfolio
Table 5.33 Takara Bio’s CD19 CAR-T: Current Status of Development
Table 5.34 Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 6.1 CAR-T Cell and TCR Based Therapies: Key Differences
Table 6.2 NY-ESO TCR: Clinical Studies
Table 6.3 MAGE-A10: Clinical Studies
Table 6.4 NY-ESO TCR / MAGE A-10: Clinical Trial Endpoints
Table 6.5 ALT-801: Clinical Studies
Table 6.6 ALT-801: Clinical Trial Endpoints
Table 6.7 IMCgp100: Clinical Studies
Table 6.8 IMCgp100: Clinical Trial Endpoints
Table 6.9 JTCR016: Clinical Studies
Table 6.10 JTCR016: Clinical Trial Endpoints
Table 6.11 WT1 TCR: Clinical Studies
Table 6.12 WT1 TCR: Clinical Trial Endpoints
Table 7.1 LN-144: Clinical Trial Endpoints
Table 7.2 LN-144: Patent Portfolio
Table 7.3 Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 7.4 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 8.1 T-Cell Immunotherapy: List of Forecasted Molecules
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2 Comparison of Marketed Targeted Therapeutics: Leukemia
Table 9.3 Comparison of Marketed Targeted Therapeutics: Lymphoma
Table 9.4 T-Cell Immunotherapy: Targets under Investigation for Leukaemia
Table 9.5 T-Cell Immunotherapy: Targets under Investigation for Lymphoma
Table 9.6 Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
Table 9.7 T-Cell Immunotherapy: Targets under Investigation for Multiple Myeloma
Table 9.8 Comparison of Marketed Targeted Therapeutics: Melanoma
Table 9.9 TIL Therapy: Historical Development of Treatment Protocols at the National Cancer Institute
Table 9.10 Comparison of Marketed Therapeutics: Lung Cancer
Table 9.11 T-Cell Immunotherapy: Targets under Investigation for Lung Cancer
Table 9.12 Comparison of Marketed Targeted Therapeutics: Renal Cell Carcinoma
Table 9.13 T-Cell Immunotherapy: Targets under Investigation for Ovarian Cancer
Table 9.14 Comparison of Marketed Therapeutics: Breast Cancer
Table 9.15 T-Cell Immunotherapy: Targets under Investigation for Breast Cancer
Table 10.1 Editas Medicine: CRISPR/Cas9 Technology, Research Publications
Table 10.2 Editas Medicine: Funding Instances
Table 10.3 Editas Medicine: Collaborations
Table 10.4 Intellia Therapeutics: CRISPR/Cas9 Technology, Research Publications
Table 10.5 Intellia Therapeutics: Funding Instances
Table 10.6 Intellia Therapeutics: Collaborations
Table 10.7 CRISPR Therapeutics: CRIPSR/Cas9 Technology, Research Publications
Table 10.8 CRISPR Therapeutics: Funding Instances
Table 10.9 CRISPR Therapeutics: Collaborations
Table 10.10 Cellectis: Funding Instances
Table 10.11 Cellectis: Collaborations
Table 10.12 bluebird bio: Funding Instances
Table 10.13 bluebird bio: Collaborations
Table 10.14 Sangamo Biosciences: Funding Instances
Table 10.15 Sangamo Biosciences: Collaborations
Table 10.16 Unum Therapeutics: Funding Instances
Table 10.17 Unum Therapeutics: Collaborations
Table 10.18 Celyad: Funding Instances
Table 10.19 Celyad: Collaborations
Table 10.20 Intrexon: Funding Instances
Table 10.21 Intrexon: Collaborations
Table 10.22 Bellicum Pharmaceuticals: Key Switch Technologies
Table 10.23 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 10.24 Bellicum Pharmaceuticals: Funding Instances
Table 10.25 Bellicum Pharmaceuticals: Collaborations
Table 10.26 Theravectys: Funding Instances
Table 10.27 Formula Pharmaceuticals: Collaborations
Table 12.1 T-Cell Immunotherapy: Recent Collaborations
Table13.1 T-Cell Immunotherapy: List of Funding Rounds / Grants and Investors Involved
Table 14.1 List of Other Novel T-Cell Immunotherapies
Table 14.2 Treg Cell: Properties
Table 15.1 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 15.2 Cell Therapy Manufacturing: Contract Manufacturers
Table 16.1 Marketed Cell / Gene Therapies: Price
Table 16.2 Marketed Targeted Drugs for Cancer: Price
Table 16.3 T-Cell Immunotherapy: Expert Opinions on Pricing
Table 17.1 Adaptimmune: T-Cell Immunotherapy Pipeline
Table 17.2 Adaptimmune: T-Cell Immunotherapy Collaborations
Table 17.3 Altor BioScience: T-Cell Immunotherapy Pipeline
Table 17.4 Altor BioScience: T-Cell Immunotherapy Collaborations
Table 17.5 bluebird bio: T-Cell Immunotherapy Pipeline
Table 17.6 bluebird bio: T-Cell Immunotherapy Collaborations
Table 17.7 Cellectis: T-Cell Immunotherapy Pipeline
Table 17.8 Cellectis: T-Cell Immunotherapy Collaborations
Table 17.9 Cellular Biomedicine Group: T-Cell Immunotherapy Pipeline
Table 17.10 Cellular Biomedicine Group: T-Cell Immunotherapy Collaborations
Table 17.11 Immunocore: T-Cell Immunotherapy Pipeline
Table 17.12 Immunocore: T-Cell Immunotherapy Collaborations
Table 17.13 Juno Therapeutics: T-Cell Immunotherapy Pipeline
Table 17.14 Juno Therapeutics: T-Cell Immunotherapy Collaborations
Table 17.15 Kite Pharma: T-Cell Immunotherapy Pipeline
Table 17.16 Kite Pharma: T-Cell Immunotherapy Collaborations
Table 17.17 Lion Biotechnologies: T-Cell Immunotherapy Pipeline
Table 17.18 Lion Biotechnologies: T-Cell Immunotherapy Collaborations
Table 17.19 Novartis: T-Cell Immunotherapy Pipeline
Table 17.20 Novartis: T-Cell Immunotherapy Collaborations
Table 17.21 Takara Bio: T-Cell Immunotherapy Pipeline
Table 17.22 Takara Bio: T-Cell Immunotherapy Collaborations
Table 17.23 Unum Therapeutics: T-Cell Immunotherapy Pipeline
Table 17.24 Unum Therapeutics: T-Cell Immunotherapy Collaborations
Table 20.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
Table 20.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
Table 20.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
Table 20.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
Table 20.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development across CAR-T, TCR and TIL
Table 20.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
Table 20.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
Table 20.8 T-Cell Immunotherapy: Popular Target Indications
Table 20.9 CAR-T Cell Immunotherapy: Popular Target Indications
Table 20.10 TCR Cell Immunotherapy: Popular Target Indications
Table 20.11 TIL Cell Immunotherapy: Popular Target Indications
Table 20.12 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
Table 20.13 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
Table 20.14 T-Cell Immunotherapy Pipeline: Active Non-Industry Players
Table 20.15 CAR-T Cell Therapy Pipeline: Distribution by Target Antigen
Table 20.16 TCR Therapy Pipeline: Distribution by Target Antigen
Table 20.17 Overall T-Cell Immunotherapy Market (Till 2030): Conservative Scenario (USD Billion)
Table 20.18 Overall T-Cell Immunotherapy Market (Till 2030): Base Scenario (USD Billion)
Table 20.19 Overall T-Cell Immunotherapy Market (Till 2030): Optimistic Scenario (USD Billion)
Table 20.20 T-Cell Therapy Market, 2020, 2025 and 2030: Conservative Scenario (USD Million)
Table 20.21 T-Cell Therapy Market, 2020, 2025 and 2030: Base Scenario (USD Million)
Table 20.22 T-Cell Therapy Market, 2020, 2025 and 2030: Optimistic Scenario (USD Million)
Table 20.23 Overall CAR-T Market Forecast (Till 2030): Conservative Scenario (USD Billion)
Table 20.24 Overall CAR-T Market Forecast (Till 2030): Base Scenario (USD Billion)
Table 20.25 Overall CAR-T Market Forecast (Till 2030): Optimistic Scenario (USD Billion)
Table 20.26 CTL019 Sales Forecast (Till 2030): Conservative Scenario (USD Million
Table 20.27 CTL019 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.28 CTL019 Sales Forecast (Till 2030): Optimistic Scenario (USD Million
Table 20.29 KTE-C19 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.30 KTE-C19 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.31 KTE-C19 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.32 JCAR015 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.33 JCAR015 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.34 JCAR015 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.35 CBM-CD30 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.36 CBM-CD30 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.37 CBM-CD30 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.38 CBM-CD20 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.39 CBM-CD20 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.40 CBM-CD20 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.41 CBM-EGFR CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.42 CBM-EGFR CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.43 CBM-EGFR CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.44 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.45 Sinobioway Cell Therapy’s CD 19CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.46 Sinobioway Cell Therapy’s CD 19 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.47 Takara Bio’s CD 19 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.48 Takara Bio’s CD 19CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.49 Takara Bio’s CD 19 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.50 GPC3 CAR-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.51 GPC3 CAR-T Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.52 GPC3 CAR-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.53 JCAR017 Sales Forecast, (Till 2030): Conservative Scenario (USD Million)
Table 20.54 JCAR017 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.55 JCAR017 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.56 Overall TCR Market Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.57 Overall TCR Market Forecast (Till 2030): Base Scenario (USD Million)
Table 20.58 Overall TCR Market Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.59 IMCgp100 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.60 IMCgp100 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.61 IMCgp100 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.62 HPV-16E6-TCR Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.63 HPV-16E6-TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.64 HPV-16E6-TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.65 NY-ESO-1 TCR Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.66 NY-ESO-1 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.67 NY-ESO-1 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.68 HBV antigen specific TCR Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.69 HBV antigen specific TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.70 HBV antigen specific TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.71 ALT-801 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.72 ALT-801 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.73 ALT-801 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.74 JTCR016 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.75 JTCR016 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.76 JTCR016 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.77 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.78 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.79 KITE-718 (MAGE A3/A6) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.80 MAGE A3 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.81 MAGE A3 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.82 MAGE A3 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.83 WT-1 TCR Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.84 WT-1 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.85 WT-1 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.86 MAGE A-10 TCR Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.87 MAGE A-10 TCR Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.88 MAGE A-10 TCR Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.89 Overall TIL Market Forecast (Till 2030): Conservative Scenario (USD Billion)
Table 20.90 Overall TIL Market Forecast (Till 2030): Base Scenario (USD Billion)
Table 20.91 Overall TIL Market Forecast (Till 2030): Optimistic Scenario (USD Billion)
Table 20.92 LN-144 Sales Market Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.93 LN-144 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.94 LN-144 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.95 Nantes University Hospital’s TIL Therapy Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 20.96 Nantes University Hospital’s TIL Therapy Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 20.97 Nantes University Hospital’s TIL Therapy Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 20.98 Netherland Cancer Institute’s TIL Therapy Sales Market Forecast, 2018-2030: Conservative Scenario (USD Million)
Table 20.99 Netherland Cancer Institute’s TIL Therapy Sales Forecast, 2018-2030: Base Scenario (USD Million)
Table 20.100 Netherland Cancer Institute’s TIL Therapy Sales Forecast, 2018-2030: Optimistic Scenario (USD Million)
Table 20.101 T-Cell Immunotherapy: Cumulative Distribution of Partnerships by Year, Pre-2011-2016
Table 20.102 T-Cell Immunotherapy: Distribution of Partnerships by Type of Model
Table 20.103 T-cell Immunotherapy: Leading Industry Collaborators
Table 20.104 T-cell immunotherapy: Leading Non-industry Collaborators
Table 20.105 T-Cell Immunotherapy: Distribution of Partnerships by Type of Therapy
Table 20.106 T-Cell Immunotherapy: Distribution of Partnerships by Product Therapy
Table 20.107 T-Cell Immunotherapy: Funding Instances, Cumulative Number of Investments by Year, pre-2009-2016
Table 20.108 T-Cell Immunotherapy: Funding Instances, Cumulative Distribution of Amount Invested by Year, pre-2009-2016 (USD Million)
Table 20.109 T-Cell Immunotherapy: Funding Instances, Distribution of Instances by Type of Funding
Table 20.110 T-Cell Immunotherapy: Funding Instances Distribution of Amount Invested by Type of Funding (USD Million)
Table 20.111 Adaptimmune: Funding Instances (USD Million)
Table 20.112 Altor BioScience: Funding Instances (USD Million)
Table 20.113 blubird bio: Funding Instances (USD Million)
Table 20.114 Cellectis: Funding Instances (USD Million)
Table 20.115 Cellular Biomedicine Group: Funding Instances (USD Million)
Table 20.116 Immunocore: Funding Instances (USD Million)
Table 20.117 Juno Therapeutics: Funding Instances (USD Million)
Table 20.118 Kite Pharma: Funding Instances (USD Million)
Table 20.119 Lion Biotechnologies: Funding Instances (USD Million)
Table 20.120 Novartis: Revenues 2011-9M 2016 (USD Billion)
Table 20.121 Novartis: Distribution of Revenues by Operating Segments, 2015 (USD Billion)
Table 20.122 Takara Bio: Revenues, 2011-2016 (JPY Million)
Table 20.123 Unum Therapeutics: Funding Instances (USD Million)
Table 20.124 T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook